SOLY - Soliton: Slow Steady Progress May Be About To Win Tattoo And Cellulite Removal Race
- Soliton shares are on a bull run owing to clearance granted by the FDA to use its Rapid Acoustic Pulse technology for short-term treatment of cellulite.
- The company also has clearance to use RAP in tattoo removal, and a commercial launch is planned for the first half of this year.
- With two multi-billion dollar markets within reach, Soliton shares look undervalued at current price of $13.8.
- Scar treatment and other market opportunities gives the company a long-term addressable target market >$20bn, whilst an acquisition by e.g. AbbVie / Abbott would make sense.
- It is still early days for Soliton. Negotiating the commercialisation hurdle will be tough but the potential of its technology supports a bullish outlook in my view.
For further details see:
Soliton: Slow, Steady Progress May Be About To Win Tattoo And Cellulite Removal Race